BioCentury | Jan 22, 2021
Emerging Company Profile

SciNeuro reunites GSK R&D vets to bring CNS therapies to China

...December series A round with Arch Venture Partners; they were joined by Boyu Capital, General Atlantic, Sequoia Capital...
...employees: 10Funds raised: $100 millionInvestors: Lilly Asia Ventures Fund, Arch Venture Partners,  Boyu General Atlantic, Sequoia Capital...
BioCentury | Jan 20, 2021
Finance

IPO queue bulges further as Adagene, NexImmune are among latest to file

...4-1BB and CTLA-4, and its investors include F-Prime Capital, Eight Roads, General Atlantic, GP Healthcare Capital, Sequoia Capital...
BioCentury | Dec 31, 2020
Finance

Dec. 30 Quick Takes: Transcenta leads year-end crop of China venture rounds

...Authority, and existing investors CCT China Merchants Fund, Lilly Asia Ventures, Teng Yue Partners, and Sequoia Capital...
BioCentury | Dec 9, 2020
Emerging Company Profile

How D3 Bio is building its biomarker-driven pipeline

...investors including Boyu Capital, Matrix Partners China, Sequoia Capital...
...$200 millionInvestors: Boyu Capital, Matrix Partners China, Sequoia Capital...
BioCentury | Nov 17, 2020
Finance

D3 Bio’s debut with $200M series A highlights China’s fast-track to global stage

...A round Tuesday backed by a syndicate of investors including Boyu Capital, Matrix Partners China, Sequoia Capital...
BioCentury | Oct 13, 2020
Finance

Oct. 13 Quick Takes: Sovereign wealth fund backs Evotec; plus Canaan, EdiGene, Cedilla, Rappta and Lassogen

...$67 million) in a series B round led by 3H Health Investment. Fellow new investors Sequoia Capital...
BioCentury | Sep 15, 2020
Finance

Sept. 14 Quick Takes: $70M+ rounds for Escient, Escape, plus Alzheimer’s data lifts Cassava shares and more

...new investor Bluestem Capital and existing investor Visionary Ventures, with participation by other returning investors Sequoia Capital...
BioCentury | Sep 10, 2020
Finance

Sept. 9 Quick Takes: OncoImmune, Inversago raise B rounds; plus Trillium-Pfizer, Biofourmis, LinkDoc, Singleron, Hrain, InxMed and MilleporeSigma

...C round for digital medicines company Biofourmis Inc. Also participating were Openspace Ventures, MassMutual Ventures, Sequoia Capital...
BioCentury | Jun 27, 2020
Deals

Why the WuXi NextCode split makes strategic sense for the multinational genomics company

...Chinese venture capital firms 3W Partners and Yunfeng Capital, Singapore investor Temasek and China-linked VC Sequoia Capital...
BioCentury | Jun 25, 2020
Emerging Company Profile

Simcha launches with $25M WuXi-led series A, new take on IL-18 for cancer

...Co. Ltd. (Shanghai:603259; HKEX:2359) led Simcha Therapeutics’ financing, which closed in May. Other investors included Sequoia Capital...
...partners: N/A Number of employees: 0 Funds raised: $25 million Investors: WuXi AppTec Co. Ltd., Sequoia Capital...
Items per page:
1 - 10 of 146
BioCentury | Jan 22, 2021
Emerging Company Profile

SciNeuro reunites GSK R&D vets to bring CNS therapies to China

...December series A round with Arch Venture Partners; they were joined by Boyu Capital, General Atlantic, Sequoia Capital...
...employees: 10Funds raised: $100 millionInvestors: Lilly Asia Ventures Fund, Arch Venture Partners,  Boyu General Atlantic, Sequoia Capital...
BioCentury | Jan 20, 2021
Finance

IPO queue bulges further as Adagene, NexImmune are among latest to file

...4-1BB and CTLA-4, and its investors include F-Prime Capital, Eight Roads, General Atlantic, GP Healthcare Capital, Sequoia Capital...
BioCentury | Dec 31, 2020
Finance

Dec. 30 Quick Takes: Transcenta leads year-end crop of China venture rounds

...Authority, and existing investors CCT China Merchants Fund, Lilly Asia Ventures, Teng Yue Partners, and Sequoia Capital...
BioCentury | Dec 9, 2020
Emerging Company Profile

How D3 Bio is building its biomarker-driven pipeline

...investors including Boyu Capital, Matrix Partners China, Sequoia Capital...
...$200 millionInvestors: Boyu Capital, Matrix Partners China, Sequoia Capital...
BioCentury | Nov 17, 2020
Finance

D3 Bio’s debut with $200M series A highlights China’s fast-track to global stage

...A round Tuesday backed by a syndicate of investors including Boyu Capital, Matrix Partners China, Sequoia Capital...
BioCentury | Oct 13, 2020
Finance

Oct. 13 Quick Takes: Sovereign wealth fund backs Evotec; plus Canaan, EdiGene, Cedilla, Rappta and Lassogen

...$67 million) in a series B round led by 3H Health Investment. Fellow new investors Sequoia Capital...
BioCentury | Sep 15, 2020
Finance

Sept. 14 Quick Takes: $70M+ rounds for Escient, Escape, plus Alzheimer’s data lifts Cassava shares and more

...new investor Bluestem Capital and existing investor Visionary Ventures, with participation by other returning investors Sequoia Capital...
BioCentury | Sep 10, 2020
Finance

Sept. 9 Quick Takes: OncoImmune, Inversago raise B rounds; plus Trillium-Pfizer, Biofourmis, LinkDoc, Singleron, Hrain, InxMed and MilleporeSigma

...C round for digital medicines company Biofourmis Inc. Also participating were Openspace Ventures, MassMutual Ventures, Sequoia Capital...
BioCentury | Jun 27, 2020
Deals

Why the WuXi NextCode split makes strategic sense for the multinational genomics company

...Chinese venture capital firms 3W Partners and Yunfeng Capital, Singapore investor Temasek and China-linked VC Sequoia Capital...
BioCentury | Jun 25, 2020
Emerging Company Profile

Simcha launches with $25M WuXi-led series A, new take on IL-18 for cancer

...Co. Ltd. (Shanghai:603259; HKEX:2359) led Simcha Therapeutics’ financing, which closed in May. Other investors included Sequoia Capital...
...partners: N/A Number of employees: 0 Funds raised: $25 million Investors: WuXi AppTec Co. Ltd., Sequoia Capital...
Items per page:
1 - 10 of 146